AbbVie Archives

News and Trends 11 Jun 2020

AbbVie and Genmab Strike €3.4B Immuno-Oncology Megadeal

AbbVie and Genmab have announced a €3.4B collaboration deal that ranks as the second biggest strategic alliance in European biotech in 2020. The partners aim to commercialize three phase I-stage antibody drugs for undisclosed types of solid and liquid cancer. Upfront, the US AbbVie will pay the Danish biotech €659M, with up to €2.77B available […]

June 11, 2020 - 3 minutesmins - By External Contributor

mission therapeutics abbvie parkinsons disease

More News! 16 Nov 2018

AbbVie Enters Industry Collaboration to Fight Alzheimer’s and Parkinson’s Disease

The UK biotech Mission Therapeutics has teamed up with AbbVie to develop new drugs to treat the neurodegenerative conditions Alzheimer’s disease and Parkinson’s disease. The new collaboration aims to fund the preclinical development of drugs that inhibit proteins called deubiquitinating enzymes. Deubiquitinating enzymes modify proteins in the cell, controlling essential functions such as what the […]

November 16, 2018 - 2 minutesmins - By Jonathan Smith

Inventiva fibrosis abbvie boehringer ingelheim

News and Trends 5 Sep 2017

French Biotech Lures Big Pharma with Fibrosis Treatments

This week, Inventiva has received a milestone payment from Boehringer Ingelheim and extended its collaboration with AbbVie. Today, Boehringer Ingelheim has decided today to take the next step forward and start development of the first candidate against idiopathic pulmonary fibrosis (IPF) from a research partnership with Inventiva. This has triggered a €2.5M payment for the French biotech, which is […]

September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 13 Apr 2017

Next-Gen Cancer Antibody Technology from Germany enters the Clinic

Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie has initiated a Phase I trial testing its next-generation immuno-oncology technology in patients suffering from solid tumors, non-Hodgkin’s lymphoma (NHL) and acute myeloid leukemia (AML). The candidate […]

April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Mar 2017

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Galapagos has announced to kick off a Phase I trial with its novel Cystic Fibrosis potentiator GLPG3067, triggering a €7M milestone payment from AbbVie. Galapagos and AbbVie teamed up in 2013, with the aim of developing a triple combination therapy for the treatment of Cystic Fibrosis (CF). Now, Galapagos announced the start of a Phase […]

March 23, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 2 Feb 2017

Galapagos kicks off a Phase IIa trial for Cystic Fibrosis

After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […]

February 2, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 29 Nov 2016

One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis

Galapagos and AbbVie are closer to launching a cystic fibrosis treatment that can outperform the current standards. However, gene therapy and CRISPR might end up taking over in the long term. Despite being abandoned by AbbVie in its rheumatoid arthritis program, Galapagos and the big US pharma expanded their cystic fibrosis partnership in May. The […]

November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Sanofi regeneron rheumatoid arthritis salurimab

News and Trends 31 Oct 2016

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […]

October 31, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2016

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Aug 2016

Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

After losing AbbVie as a partner, Galapagos has pressed on with Gilead in the development of filgotinib for rheumatoid arthritis. Phase III trials have officially begun! Galapagos is making progress as its rheumatoid arthritis drug, filgotinib, enters Phase III clinical trials. This comes after a major setback when its deal with AbbVie fell through last fall. It’s not […]

August 25, 2016 - 2 minutesmins - By Evelyn Warner

rheumatoid arthritis anti il 6r ablynx abbvie

News and Trends 9 Aug 2016

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

Ablynx has disclosed ‘compelling’ results for its Phase IIb trial in rheumatoid arthritis. But it might have a hard time compelling AbbVie to pay €68M to continue the candidate’s development, as the grass is not as green as it seems… Ablynx‘s impressive list of big Pharma collaborations could soon need an update, as its $840 partnership with […]

August 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

abbvie ablynx rheumatoid arthritis nanobody

News and Trends 11 Jul 2016

Nanobody Phase II Results for Arthritis: Good but not good enough?

Ablynx has shown that its candidate for Rheumatoid arthritis could work as a monotherapy, but whether they can convince AbbVie to stick to the previous $840M deal is still unclear. Ghent-based Ablynx has hooked several big Pharmas with its Nanobody platform, based on the shorter monoclonal antibodies of llamas. One of these is AbbVie (France), which is […]

July 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us